---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-25-001570"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:09:36.537670+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Immunic Q3 2025 net loss $25.6M; cash $35.1M; warns insufficient liquidity for 12 months

## Summary
- Net loss of $25.6M ($0.13/share) vs $24.4M ($0.24/share) in Q3 2024; nine-month loss $77.9M.
- Cash and equivalents $35.1M as of Sep 30, 2025; company states it lacks adequate liquidity to fund operations for 12 months without additional capital.
- R&D expenses $20.0M, down from $21.4M; G&A $6.0M, up from $4.4M.
- At ECTRIMS, presented CALLIPER data showing statistically significant 24-week confirmed disability improvement in progressive MS.
- Received USPTO Notice of Allowance for patent covering vidofludimus calcium dose strengths for PMS; top-line ENSURE data expected by year-end 2026.

## SEC filing metadata
- accession: 0001193805-25-001570
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380525001570/0001193805-25-001570-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380525001570/e664954_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-25-001570
- JSON: https://secwatch.observer/filing/0001193805-25-001570.json
- Plain text: https://secwatch.observer/filing/0001193805-25-001570.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.